18F-Fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 6, 2013, Pages 865-873

  Song, Myeong Jun ^a   Bae, Si Hyun ^a   Lee, Sung Won ^a   Song, Do Sun ^a   Kim, Hee Yeon ^a   Yoo, Ie Ryung ^a   Choi, Joon Il ^a   Lee, Young June ^a   Chun, Ho Jong ^a   Lee, Hae Giu ^a   Choi, Jong Young ^a   Yoon, Seung Kew ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Prognosis; Time to progression; Transarterial chemoembolization; Treatment response

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; IODINATED POPPYSEED OIL; IOPROMIDE; DIAGNOSTIC AGENT;

ADULT; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG UPTAKE; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PET SCANNER; PREDICTIVE VALUE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ADOLESCENT; AGED; ARTERY; ARTIFICIAL EMBOLISM; DISEASE COURSE; LIVER TUMOR; MULTIMODAL IMAGING; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; TIME; TREATMENT OUTCOME; YOUNG ADULT; CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC USE; LIVER NEOPLASMS;

ADOLESCENT; ADULT; AGED; ARTERIES; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; EMBOLIZATION, THERAPEUTIC; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891668748     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2366-2     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-17. doi:10.1016/S0140-6736(03)14964-1.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-2. doi:10.1002/hep.24199.
4. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502-10. doi:10.1111/j.1478-3231.2008.01957.x.
5. 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Eur J Radiol. 2012;81:2417-22. doi:10.1016/j.ejrad.2011.08.004.
6. Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. 1999;94:3314-9. doi:10.1111/j.1572-0241.1999. 01544.x.
7. 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging. 2004;31:1621-30. doi:10.1007/s00259-004- 1602-1.
8. Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, et al. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl. 2006;12:1655-60. doi:10.1002/lt.20861.
9. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60. doi:10.1055/s-0030- 1247132.
10. Busk M, Horsman MR, Kristjansen PE, van der Kogel AJ, Bussink J, Overgaard J. Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose- PET as markers of tissue hypoxia. Int J Cancer. 2008;122:2726-34. doi:10.1002/ijc.23449.
11. Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, et al. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol. 2009;174:1544-52. doi:10.2353/ajpath.2009.080596.
12. Mocherla B, Kim J, Roayaie S, Kim S, Machac J, Kostakoglu L. FDG PET/CT imaging to rule out extrahepatic metastases before liver transplantation. Clin Nucl Med. 2007;32:947-8. doi:10.1097/RLU.0b013e3181598cef.
13. Higashi T, Hatano E, Ikai I, Nishii R, Nakamoto Y, Ishizu K, et al. FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:468-82. doi:10.1007/s00259-009- 1284-9.
14. 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Liver Int. 2011;31:1144-9. doi:10.1111/j.1478-3231.2011.02541.x.
15. Kornberg A, Kupper B, Tannapfel A, Buchler P, Krause B, Witt U, et al. Patients with non-[18F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. Liver Transpl. 2012;18:53-61. doi:10.1002/lt.22416.
16. 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol. 2012;18:3215-22. doi:10.3748/wjg.v18.i25.3215.
17. Ahn SG, Kim SH, Jeon TJ, Cho HJ, Choi SB, Yun MJ, et al. The role of preoperative [18F]fluorodeoxyglucose positron emission tomography in predicting early recurrence after curative resection of hepatocellular carcinomas. J Gastrointest Surg. 2011;15:2044-52. doi:10.1007/s11605-011-1660-1.
18. Kim BK, Kang WJ, Kim JK, Seong J, Park JY, Kim do Y. (18) F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer. 2011;117:4779-87. doi:10.1002/cncr.26099.
19. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698-711. doi:10.1093/jnci/djn134.
20. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-9. doi:10.1016/S0140-6736(02)08649-X.
21. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004;127:S179-88.
22. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762-73. doi:10.1002/hep.23725.
23. Iwata Y, Shiomi S, Sasaki N, Jomura H, Nishiguchi S, Seki S, et al. Clinical usefulness of positron emission tomography with fluorine- 18-fluorodeoxyglucose in the diagnosis of liver tumors. Ann Nucl Med. 2000;14:121-6.
24. Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med. 1995;36:1811-7.
25. 18F-FDG PET. J Nucl Med. 2008;49:1245-8. doi:10.2967/jnumed.108. 052639.
26. Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res. 2007;13:427-33. doi:10.1158/1078-0432.CCR-06-1357.
27. Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet. 1967;2:1051-6.
28. Petrides AS, DeFronzo RA. Glucose metabolism in cirrhosis: a review with some perspectives for the future. Diabetes Metab Rev. 1989;5:691-709.
29. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol. 2004;39:961-8. doi:10.1007/s00535- 004-1427-5.
30. Ledoux S, Yang R, Friedlander G, Laouari D. Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res. 2003;63:7284-90.
31. Song MJ, Chun HJ, Song do S, Kim HY, Yoo SH, Park CH, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012;57:1244-50. doi:10.1016/j.jhep.2012.07.017.
32. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920-8. doi:10.1111/j.1600-6143.2009.02695.x.
33. Chiesa C, Maccauro M, Romito R, Spreafico C, Pellizzari S, Negri A, et al. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging. 2011;55:168-97.
34. Garin E, Lenoir L, Rolland Y, Edeline J, Mesbah H, Laffont S, et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53:255-63. doi:10.2967/jnumed.111.094235.
35. Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology. 2011;141:526-35, 535 e1-2. doi:10.1053/j.gastro.2011.04.054.